featured
Triplet Combination of Durvalumab, Tremelimumab, and Paclitaxel in Biliary Tract Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
European Journal of Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Triplet Combination of Durvalumab, Tremelimumab, and Paclitaxel in Biliary Tract Carcinomas: Safety Run-in Results of the Randomized IMMUNOBIL PRODIGE 57 Phase II Trial
Eur. J. Cancer 2021 Jan 01;143(xx)55-63, A Boilève, M Hilmi, P Gougis, R Cohen, B Rousseau, JF Blanc, M Ben Abdelghani, H Castanié, L Dahan, D Tougeron, JP Metges, C Tournigand, ML Garcia-Larnicol, D Vernerey, A Turpin, C NeuzilletFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.